NCT06357910View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers Under Fed Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 17, 2024

Primary Completion Date

July 1, 2024

Study Completion Date

July 1, 2024

Conditions
Healthy
Interventions
DRUG

HCP2303

Take 1 tablet once per period

DRUG

RLD2302

Take 1 tablet once per period

DRUG

RLD2102

Take 1 tablet once per period

Trial Locations (1)

Unknown

Jeonbuk University Hospital, Jeonju

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY